Daniel Oliver, MD

Cancer Focus:
Brain Cancer, Glioblastoma, Meningioma, Pituitary Macroadenoma, Pituitary Microadenoma, Pituitary Neoplasm, Spinal Tumor

Dr. Daniel Oliver is an Assistant Member in the Section of Neuro-Oncology and Supportive Care in the Moffitt Cancer Center Department of Radiation Oncology. Prior to medical school, Dr. Oliver served on the faculties of music (cello) at University of Alaska-Fairbanks and Emory University. He received his MD from Emory University School of Medicine and completed a Radiation Oncology Residency at Moffitt Cancer Center/University of South Florida. Dr. Oliver’s clinical interests are in the use of stereotactic and conventional radiation therapy to treat patients with primary and metastatic tumors of the brain and spine. His research interests focus on improving outcomes in early metastatic disease through a multidisciplinary treatment approach and advanced radiotherapy techniques. He will also be exploring the use of artificial intelligence and personalized care models as part of the FORT (Future of Radiation Therapy) departmental research programs, especially as it pertains to pre-emptively predicting toxicity and trying to avoid adverse events.

• Nasser N, Perez BA, Penagaricano JA, Caudell JJ, Oliver DE, Latifi K, Moros EG, Redler G. Technical feasibility of novel immunostimulatory low-dose radiation for polymetastatic disease with CBCT-based online adaptive and conventional approaches. J Appl Clin Med Phys. 2024 Feb.e14303. Pubmedid: 38377378.
• Tang JD, Mills MN, Nakashima J, Dohm AE, Khushalani NI, Forsyth PA, Vogelbaum MA, Wuthrick EJ, Yu HM, Oliver DE, Liu JKC, Ahmed KA. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery. J Neurooncol. 2024 Feb.166(3):431-440. Pubmedid: 38310157.
• Dohm AE, Nakashima JY, Kalagotla H, Jiang SX, Tang JD, Bhandari M, Kim Y, Graham JA, Khushalani NI, Forsyth PA, Etame AB, Liu JK, Tran ND, Vogelbaum MA, Wuthrick EJ, Yu HM, Oliver DE, Ahmed KA. Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases. Eur J Cancer. 2023 Oct.192:113287. Pubmedid: 37657227.
• Bryant JM, Doniparthi A, Weygand J, Cruz-Chamorro R, Oraiqat IM, Andreozzi J, Graham J, Redler G, Latifi K, Feygelman V, Rosenberg SA, Yu HM, Oliver DE. Treatment of Central Nervous System Tumors on Combination MR-Linear Accelerators: Review of Current Practice and Future Directions. Cancers (Basel). 2023 Oct.15(21). Pubmedid: 37958374. Pmcid: PMC10649155.
• Oliver DE, Laborde JM, Singh DP, Milano MT, Videtic GM, Williams GR, Lariviere MJ, Chan JW, Peters GW, Decker RH, Samson P, Robinson CG, Breen WG, Owen D, Tian S, Higgins KA, Almeldin D, Jabbour SK, Wang F, Grass GD, Perez BA, Dilling TJ, Strosberg J, Rosenberg SA. Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):849-857. Pubmedid: 36708788.
• Khatri VM, Mills MN, Oliver DE, Yu HM, Vogelbaum MA, Forsyth PA, Soliman HH, Han HS, Ahmed KA. Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases. J Neurooncol. 2023 Aug.164(1):191-197. Pubmedid: 37490232.
• Oliver DE, Yu HM, Ahmed KA. The Lung Graded Prognostic Assessment: Continued Evolution of Brain Metastases Prognostication. Int J Radiat Oncol Biol Phys. 2022 Sep.114(1):75-77. Pubmedid: 35964633.
• Dohm AE, Tang JD, Mills MN, Liveringhouse CL, Sandoval ML, Perez BA, Robinson TJ, Creelan BC, Gray JE, Etame AB, Vogelbaum MA, Forsyth P, Yu HM, Oliver DE, Ahmed KA. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. J Neurosurg. 2022 Nov.1-8. Pubmedid: 36681988.
• Rubino S, Oliver DE, Tran ND, Vogelbaum MA, Forsyth PA, Yu HM, Ahmed K, Etame AB. Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. Front Oncol. 2022 Mar.12:854402. Pubmedid: 35311078. Pmcid: PMC8924127.
• Graham JA, Redler G, Delozier KB, Yu HM, Oliver DE, Rosenberg SA. Dosimetric feasibility of hippocampal avoidance whole brain radiotherapy with an MRI-guided linear accelerator. J Appl Clin Med Phys. 2022 Jun.23(6):e13587. Pubmedid: 35344266. Pmcid: PMC9195042.
• Dohm AE, Oliver DE, Michael Yu HH, Ahmed KA. Commentary: From Postoperative to Preoperative: A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases. Oper Neurosurg (Hagerstown). 2022 Jun.22(6):e283-e284. Pubmedid: 35404318.
• Kutuk T, Grass GD, Oliver D, Mokhtari S, Sahebjam S, Kim S, Penagaricano J, Yu HM, Tran N, Etame A, Peterson JL, Forsyth P, Robinson T. Revisiting the Concept of Recurrence of Primary Central Nervous System Lymphomas After Complete Response to Methotrexate-Based Therapy: Periventricular Reseeding as the Predominant Mechanism of Recurrence. Adv Radiat Oncol. 2022 Jul.7(4):100940. Pubmedid: 35814853. Pmcid: PMC9260129.
• Mills MN, Potluri TK, Kawahara Y, Fahey M, Figura NB, Soyano AE, Washington IR, Diaz R, Oliver DE, Yu HM, Etame AB, Vogelbaum MA, Czerniecki BJ, Arrington JA, Sahebjam S, Forsyth PA, Soliman HH, Han HS, Ahmed KA. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs. Breast Cancer Res Treat. 2022 Jan.191(1):209-217. Pubmedid: 34669082.
• Lowe SR, Wang CP, Brisco A, Whiting J, Arrington J, Ahmed K, Yu M, Robinson T, Oliver D, Etame A, Tran N, Beer Furlan A, Sahebjam S, Mokhtari S, Piña Y, Macaulay R, Forsyth P, Vogelbaum MA, Liu JKC. Surgical and anatomic factors predict development of leptomeningeal disease in patients with melanoma brain metastases. Neurooncol. 2022 Aug.24(8):1307-1317. Pubmedid: 35092434. Pmcid: PMC9340645.
• Scott JG, Sedor G, Ellsworth P, Scarborough JA, Ahmed KA, Oliver DE, Eschrich SA, Kattan MW, Torres-Roca JF. Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis. Lancet Oncol. 2021 Sep.22(9):1221-1229. Pubmedid: 34363761.
• Mills MN, Naz A, Thawani C, Walker C, Figura NB, Kushchayev S, Oliver DE, Etame AB, Yu HM, Robinson TJ, Liu JKC, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Capecitabine and stereotactic radiation in the management of breast cancer brain metastases. BMC Cancer. 2021 May.21(1):552. Pubmedid: 33992087. Pmcid: PMC8126143.
• Mills MN, Thawani C, Figura NB, Oliver DE, Soyano AE, Etame A, Robinson TJ, Liu JK, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Yu HM, Ahmed KA. Breast cancer subtype predicts clinical outcomes after stereotactic radiation for brain metastases. J Neurooncol. 2021 May.152(3):591-601. Pubmedid: 33742358.
• Koo J, Nardella L, Degnan M, Andreozzi J, Yu HM, Penagaricano J, Johnstone PAS, Oliver D, Ahmed K, Rosenberg SA, Wuthrick E, Diaz R, Feygelman V, Latifi K, Moros EG, Redler G. Triggered kV Imaging During Spine SBRT for Intrafraction Motion Management. Technol Cancer Res Treat. 2021 Jan.20. Pubmedid: 34855577. Pmcid: PMC8649431.
• Sim AJ, Ahmed KA, Keller A, Figura NB, Oliver DE, Sarangkasiri S, Robinson TJ, Johnstone PAS, Yu HM, Naghavi AO. Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases. Am J Clin Oncol. 2020 May.43(5):356-361. Pubmedid: 32217854.
• Yang G, Mills M, Kim Y, Figura NB, Doyle C, Oliver D, Grass GD, Robinson T, Chavez J, Kim S. Enhancement of the Follicular Lymphoma International Prognostic Index (FLIPI) with lymphopenia (FLIPI-L): a predictor for overall survival and histologic transformation. Blood Cancer J. 2020 Jan.9(12):104. Pubmedid: 31894139. Pmcid: PMC6938796.
• Figura NB, Oliver DE, Mohammadi H, Martinez K, Grass GD, Hoffe SE, Johnstone PAS, Frakes JM. Novel Dose Escalation Approaches for Stereotactic Body Radiotherapy to Adrenal Oligometastases: A Single-Institution Experience. Am J Clin Oncol. 2020 Feb.43(2):107-114. Pubmedid: 31764023.
• Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PAS. The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. Cancer. 2019 Feb.125(4):642-651. Pubmedid: 30644538.
• Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Ann Surg Oncol. 2019 Feb.26(2):379-385. Pubmedid: 30311164. Pmcid: PMC7771265.
• Figura NB, Potluri TK, Mohammadi H, Oliver DE, Arrington JA, Robinson TJ, Etame AB, Tran ND, Liu JK, Soliman H, Forsyth PA, Sahebjam S, Yu HM, Han HS, Ahmed KA. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J Neurooncol. 2019 Aug.144(3):583-589. Pubmedid: 31399935.
• Oliver DE, Mohammadi H, Figura N, Frakes JM, Yamoah K, Perez BA, Wuthrick EJ, Naghavi AO, Caudell JJ, Harrison LB, Torres-Roca JF, Ahmed KA. Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Semin Radiat Oncol. 2019 Apr.29(2):111-125. Pubmedid: 30827449.
• Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Ann Surg Oncol. 2018 Oct.25(11):3334-3340. Pubmedid: 30073600. Pmcid: PMC7771268.
• Oliver DE, Sondak VK, Strom T, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Manag. 2018 Jun.5(1):MMT02. Pubmedid: 30190928. Pmcid: PMC6122528.
• Armanious MA, Mohammadi H, Khodor S, Oliver DE, Johnstone PA, Fradley MG. Cardiovascular effects of radiation therapy. Curr Prob Cancer. 2018 Jul.42(4):433-442. Pubmedid: 30006103.
• Mills MN, Yang GQ, Oliver DE, Liveringhouse CL, Ahmed KA, Orman AG, Laronga C, Hoover SJ, Khakpour N, Costa RLB, Diaz R. Histologic heterogeneity of triple negative breast cancer: A National Cancer Centre Database analysis. Eur J Cancer. 2018 Jul.98:48-58. Pubmedid: 29870876.
• Oliver DE, Donnelly OG, Grass GD, Naghavi AO, Yang GQ, Dilling TJ, Perez BA. Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation. J Thorac Dis. 2018 Jul.10(7):4321-4327. Pubmedid: 30174879. Pmcid: PMC6106034.
• Yuan Z, Fromm A, Ahmed KA, Grass GD, Yang GQ, Oliver DE, Dilling TJ, Antonia SJ, Perez BA. Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung. J Thorac Oncol. 2017 Sep.12(9):e135-e136. Pubmedid: 28502722.
• Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, Khosa F, Liu Y, Khan MK. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol. 2017 Oct.40(5):444-450. Pubmedid: 26017484.
• Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Ne. 2017 Apr.15(4):473-482. Pubmedid: 28404758. Pmcid: PMC7771284.
• Oliver DE, Patel KR, Switchenko J, Parker D, Lawson DH, Delman KA, Kudchadkar RR, Khan MK. Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res. 2016 Feb.26(1):35-41. Pubmedid: 26397051. Pmcid: PMC4869869.
• Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, Ahmed R, Khan MK. Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neurooncol. 2015 Oct.17(10):1312-1321. Pubmedid: 26014049. Pmcid: PMC4578585.
• Oliver DE, Patel KR, Parker D, Delman KA, Lawson DH, Kudchadkar RR, Khan MK. The emerging role of radiotherapy for desmoplastic melanoma and implications for future research. Melanoma Res. 2015 Apr.25(2):95-102. Pubmedid: 25588202.
• Patel KR, Prabhu RS, Kandula S, Oliver DE, Kim S, Hadjipanayis C, Olson JJ, Oyesiku N, Curran WJ, Khan MK, Shu HK, Crocker I. Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases: whole brain radiotherapy versus stereotactic radiosurgery alone. J Neurooncol. 2014 Dec.120(3):657-663. Pubmedid: 25189789.